OF
KRYS icon

Optimize Financial’s Krystal Biotech KRYS Stock Holding History

Optimize Financial’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$634K Sell
1,705
-5
-0.3% -$1.49K 0.23% 83
2026
Q1 		$442K Sell
1,710
-1,145
-40% -$305K 0.22% 155
2025
Q4 		$704K Buy
2,855
+40
+1% +$8.42K 0.35% 67
2025
Q3 		$497K Buy
+2,815
New +$421K 0.26% 113

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Optimize Financial's KRYS Position: Q2 2026 in Review

Optimize Financial reduced its Krystal Biotech (KRYS) stake by 0.29% in Q2 2026, selling an estimated $1.49K and leaving 1,705 shares worth $634K. The position accounts for 0.23% of the portfolio, ranked #83.

Optimize Financial first reported a position in KRYS in Q3 2025 and has held it in 4 quarters since. The position peaked at $704K in Q4 2025. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Optimize Financial held 1,705 shares of Krystal Biotech worth $634K as of Q2 2026.
  • Optimize Financial sold 5 Krystal Biotech shares in Q2 2026, an estimated $1.49K.
  • Krystal Biotech made up 0.23% of Optimize Financial's portfolio in Q2 2026, its #83 holding.
  • Optimize Financial first reported a position in Krystal Biotech in Q3 2025 and has held it in 4 quarters since.
  • Optimize Financial's Krystal Biotech position peaked at $704K in Q4 2025.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Optimize Financial's 13F filing for Q2 2026, filed 27 Aug 2026.